付远辉查看源代码讨论查看历史
|
付远辉，男，北京交通大学副教授。
人物简历
教育背景
2009年6月毕业于中国疾病预防控制中心病毒病预防控制所，获得医学博士学位。
工作经历
2009年7月至今 北京交通大学理学院，一直从事病毒新型疫苗和病毒溶瘤方面的研究，作为主要成员先后参与和完成 “十二五”传染病重大专项、“十二五”新药创制重大专项、国家自然科学基金等项目多项，已在国内外高水平学术期刊发表论文30余篇，申请中国发明专利6项，授权中国发明专利3项。
研究方向
生物化学与分子生物学
细胞生物学
科研项目
（1）联合研发项目（KSL18015530），初免-加强型呼吸道合胞病毒载体疫苗，2018/05-2038/05，2000万元，参加
（2）国家自然科学基金“面上”项目：人呼吸道合胞病毒复制缺陷型活疫苗与减毒活疫苗：免疫原性及安全性的比较研究，2018/01-2021/12，55万元，参加
（3）校基本科研业务费，2014JBM123，呼吸道合胞病毒病毒样颗粒黏膜免疫评价，2014/01－2014/12，8万元，主持
（4）国家重大专项(民口)，2013ZX10004601，基于化学基因组学的病原诊治生物标志物高通量筛选平台，2013/01－2015/12，1578万元，参加
（5）国家重大专项(民口)，2013ZX09103003-011，呼吸道合胞病毒减毒活疫苗研制，2013/01－2015/12，132.32万元，参加
（6）校人才基金，2012RC050，呼吸道合胞病毒病毒样颗粒制备及其免疫保护作用研究，2013/01－2014/12，2万元，主持
（7）中国博士后科学基金，20100470196，靶向树突状细胞的呼吸道合胞病毒核酸疫苗的免疫效果研究，2010/09－2011/07，3万元，主持
（8）校基本科研业务费，2009JBM104，以抗DEC205单链抗体靶向树突状细胞提高腺病毒载体疫苗免疫效果，2010/01－2011/12，5万元，主持
（9）国家自然科学基金面上项目，30972604，提高以腺病毒载体为基础的呼吸道合胞病毒疫苗安全性和有效性的方法研究，2010/01－2012/12，32.0万元，参加
（10）北京市自然基金面上项目，7092053，呼吸道合胞病毒疫苗初免-加强免疫策略的研究，2009/01－2011/12/，12.0万元，参加
学术成果
论文/期刊
Jie‑Mei Yu, Yuan‑Hui Fu, Xiang‑Lei Peng, Yan‑Peng Zheng & Jin‑Sheng He. Genetic diversity and molecular evolution of human respiratory syncytial virus A and B, Scientific Reports (2021) 11:12941,
Li-Nan Wang, Xiang-Lei Peng, Min Xu, Yuan-Bo Zheng, Yue-Ying Jiao, Jie-Mei Yu, Yuan-Hui Fu, Yan-Peng Zheng, Wu-Yang Zhu, Zhong-Jun Dong, Jin-Sheng He, Evaluation of the Safety and Immune Efficacy of Recombinant Human Respiratory Syncytial Virus Strain Long Live Attenuated Vaccine Candidates. Virologica Sinica, 2021, DOI: 10.1007/s12250-021-00345-3
Minghua Wang, Guoning Zhang, Jianyuan Zhao, Ningning Cheng, Yujia Wang, Yuanhui Fu, Yanpeng Zheng, Juxian Wang, Mei Zhu, Shan Cen, Jinsheng He, Yucheng Wang. Synthesis and antiviral activity of a series of novel quinolone derivatives as anti-RSV or anti-IAV agents. European Journal of Medicinal Chemistry, 214 (2021) 113208, DOI: 10.1016/j.ejmech.2021.113208
Jie-Mei Yu, Li-Shu Zhang, Yuan-Hui Fu, Feng-Min Ji, Han-Li Xu, Jia-Qiang Huang, Xiang-Lei Peng, Yan-Peng Zheng, Ying Zhang and Jin-Sheng He. Analysis of Continuous Mutation and Evolution on Circulating SARS-CoV-2. Evolutionary Bioinformatics, 2020, Volume 16: 1–6, DOI: 10.1177/1176934320954870
Guo-Ning Zhang, Qiang Li, Jianyuan Zhao, Xuandi Zhang, Zhuxin Xu, Yujia Wang, Yuanhui Fu, Qi Shan, Yanpeng Zheng, Juxian Wang, Mei Zhu, Ziqiang Li, Shan Cen, Jinsheng He, Yucheng Wang. Design and synthesis of 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides as novel dual inhibitors of respiratory syncytial virus and influenza virus A. European Journal of Medicinal Chemistry, 186 (2020) 111861
Yuan-Hui Fu; Zhu-Xin Xu; Nan Jiang; Yan-Peng Zheng; Marie-Anne Rameix-Welti; Yue-Ying Jiao; Xiang-Lei Peng; Ye Wang; Jean-Francois Eleouet; Shan Cen; Jinsheng He. High-throughput screening of active compounds against human respiratory syncytial virus. Virology, 535 (2019) 171–178
Yao Ma, Yue-Ying Jiao, Yun-Zhou Yu, Nan Jiang, Ying Hua, Xiu-Juan Zhang, Yuan-Hui Fu, Xiang-Lei Peng, Yan-Peng Zheng, Larry J. Anderson, and Jin-Sheng He. A Built-In CpG Adjuvant in RSV F Protein DNA Vaccine Drives a Th1 Polarized and Enhanced Protective Immune Response. Viruses 2018, 10, 38; doi:10.3390/v10010038.
Min Xu, Yue-Ying Jiao, Yuan-Hui Fu, Nan Jiang, Yuan-Bo Zheng, Yi-Fei Yan, Mei Zhang, Yan-Peng Zheng, Wu-Yang Zhu, Xiang-Lei Peng, Jin-Sheng He. Construction and characterization of a recombinant human respiratory syncytial virus encoding enhanced green fluorescence protein for antiviral drug screening assay. BioMed Research International, Volume 2018, Article ID 8431243, 8 pages，
Yue-Ying Jiao, Yuan-Hui Fu, Yi-Fei Yan, Ying Hua, Yao Ma, Xiu-Juan Zhang, Jing-Dong Song, Xiang-Lei Peng, Jiaqiang Huang, Tao Hong, Jin-Sheng He. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus. Antiviral Research, 2017，144： 57-69.
Ying Hua, Yue-Ying Jiao, Yao Ma, Xiang-Lei Peng, Yuan-Hui Fu, Xiu-Juan Zhang, Yuan-Bo Zheng, Yan-Peng Zheng, Tao Hong, Jin-Sheng He. Enhanced humoral and CD8 + T cell immunity in mice vaccinated by DNA vaccine against human respiratory syncytial virus through targeting the encoded F protein to dendritic cells. International Immunopharmacology, 2017, dx.doi.org/10.1016/j.intimp.2017，46：62-69
Yuan-Hui Fu, Ya-Ru Liu, Yan-Peng Zheng, Nan Jiang, Yue-Ying-Jiao, Yao Ma, Wei Li, Xiang-lei Peng, Jinsheng He. An RNA polymerase I-driven human respiratory syncytial virus minigenome as a tool for quantifying virus titers and screening antiviral drug. Chinese Chemical Letters, 2017, 28: 131-135
Ying Hua, Yue-Ying Jiao, Yao Ma, Xiang-Lei Peng, Yuan-Hui Fu, Yan-Peng Zheng, Tao Hong, Jin-Sheng He. DNA Vaccine Encoding Central Conserved Region of G Protein Induces Th1 Predominant Immune Response and Protection from RSV Infection in Mice. Immunology Letters, 2016，179：95-101
Yuan-Hui Fu, Yue-Ying Jiao, Jinsheng He, Gui-Yun Jiang, Wei Zhang Yao, Ma Ying Zhang, Chang-Xin Shi, Xiang-Lei Peng, Tao Hong, Yi-Fei Yan. Sublingual administration of a helper-dependent adenoviral vector expressing the codon-optimized soluble fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in mice. Antiviral Research 105 (2014), 72-79, DOI: 10.1016/j.antiviral.2014.02.003
Yuan-hui Fu, Jin-sheng He, Wei Qiao, Yue-ying Jiao, Ying Hua, Ying Zhang, Xiang-Lei Peng, and Tao Hong. Intranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice. Virol J, 2013, 10:183. DOI: 10.1186/1743-422X-10-183
Zheng YP, Tang Y, Fu YH, He JS,Wang XB, Hong T. Purification of human respiratory syncytial virus fusion glycoprotein. Protein Expr. Purif, 2012, 81(1): 115-118
Yuan-hui Fu, Rui-juan Lv, Li-ri Jin, Qiang Lu, Xiao-qiu Shao, Jin-sheng He, Li-wen Wu, Li-shu Zhang, Hong-gang Hu. Association of apolipoprotein E polymorphisms with temporal lobeepilepsy in a Chinese Han population. Epilepsy Res, 2010, 91(2-3): 253-259
Yuan-hui Fu, Jin-sheng He, Xiao-bo Wang, Xian-Xian Zheng, Qiang Wu, Can Xie, Wei Wei, Qian Tang, Jing-Dong Song, Jian-Guo Qu, Tao Hong. A prime–boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protectiveimmunity against human respiratory syncytial virus. Biochem Biophys Res Commun, 2010, 395(1): 87-92
Yuanhui Fu, Jinsheng He, Xianxian Zheng, Xiao-bo Wang, Can Xie, Chang-xin Shi, Mei Zhang, Qian Tang, Wei Wei, Jian-guo Qu and Tao Hong. Intranasal vaccination with a helper-dependent adenovirus vector enhances transgene-specific immune responses in BALB/c mice. Biochem Biophys Res Commun, 2010, 391(1): 857-861
Yuanhui Fu, Jinsheng He, Xianxian Zheng, Qiang Wu, Mei Zhang, Xiaobo Wang, Yan Wang, Can Xie, Qian Tang, Wei Wei, Min Wang, Jingdong Song, Jianguo Qu, Ying Zhang, Xin Wang, Tao Hong. Intranasal Immunization with a Replication-Deficient Adenoviral Vector Expressing the Fusion Glycoprotein of Respiratory Syncytial Virus Elicits Protective Immunity in BALB/c Mice. Biochem Biophys Res Commun, 2009, 381(4):528-532
专利
1、发明人：何金生；付远辉；刘美琴；彭向雷；郑妍鹏；黄蕾，中国发明专利：呼吸道合胞病毒全长融合前融合糖蛋白核苷酸序列、 重组腺病毒载体及其应用产品，专利号：ZL 202010863762.X，授权公告日：2022年09月30日。
2、发明人：何金生；付远辉；彭向雷；郑妍鹏，中国发明专利：一种共表达呼吸道合胞病毒融合前蛋白和黏附糖蛋白的复制缺陷型腺病毒载体疫苗，专利号：ZL 202010864874.7，授权公告日：2022年09月05日。
3、发明人：何金生；杜琳；付远辉；朱卫华；彭向雷；高博；郑妍鹏；刘美琴， 中国发明专利：一种针对呼吸道合胞病毒感染的组合疫苗，专利号：ZL 202010863764.9，授权公告日：2022年06月15日。
4、发明人：何金生；马尧；付远辉；彭向雷；郑妍鹏，中国发明专利：一种呼吸道合胞病毒融合前F蛋白及其应用，专利号：ZL 201910337141.5，授权公告日：2021年09月10日。
5、发明人：何金生；王玉成；付远辉；张国宁；徐竹欣；李强；郑妍鹏；王菊仙；彭向雷；白晓光，中国发明专利：一类3-位官能团化的N(O,S)-杂茚类衍生物及其在抗呼吸道合胞病毒中的应用，专利号：ZL 201810109813.2，授权公告日：2020年09月24日。
6、发明人：何金生；彭向雷；许敏；付远辉，中国发明专利：基于反向遗传学构建的ＲＳＶ反基因组质粒及其应用，专利号：201710574632.2，授权公告日：2020年03月05日。
7、发明人：何金生；付远辉；彭向雷；郑研鹏；姜男；许敏，中国发明专利：一种呼吸道合胞病毒药物的高通量筛选方法和应用，专利号：ZL201710244050.8，授权公告日：2019年07月04日。
8、发明人：何金生；付远辉；焦月盈；洪涛，中国发明专利：一种呼吸道合胞病毒病毒样颗粒及其制备方法和应用，专利号：ZL 201310667523.7，授权公告日：2016年08月24日。[1]